b cell chronic lymphocytic leukemia
Current location: China paper Ce Medi Med text ZAP-70 in 24 cases of B cell chronic lymphocytic leukemia research
China paper Center [ ] Editor: studa20
Of: Wu Yujie, yong, Zhu Guangrong, Song Jun Hong, Xiao Bing
Abstract chronic lymphocytic leukemia in order to study the zeta-chain associated protein -70 (zeta-associated protein-70, ZAP-70) expression and its correlation with other prognostic factors, applied four-color flow cytometry of 24 cases B cell chronic lymphocytic leukemia (B-CLL) leukemia cells in bone marrow or peripheral blood ZAP-70 and CD38 expression. The results showed that: 37.5% B-CLL patients express ZAP-70, which Binet A, 20% of patients (3 / 15) the expression of ZAP-70, Binet BC 66.7% of patients (6 / 9), the expression of ZAP-70, ZAP-70 expression and Binet BC Binet A period of significant difference between (P 0.05). It is concluded that ZAP-70 protein can be routinely measured by flow cytometry in the laboratory.High expression of ZAP-70 is correlated with other prognostic factors such as clinic stage, chromosome abnormalities and CD38 in B-CLL.
Key words chronic lymphocytic leukemia; ZAP-70; CD38
Zeta chain associated protein -70 (zeta chain associated protein-70, ZAP-70) is associated with the TCR 70 kDa protein tyrosine kinase (PTK), widely expressed in T cells and NK cells by the TCR after stimulation could induce the activation of the double phosphorylation of T cell signaling pathways. Normal B lymphocytes lack ZAP-70, i
n B cell signal transduction, and the other PTK-Syk through the B cell antigen receptor (BCR) complex and ZAP-70 plays a similar role. Part of the B-cell chronic lymphocytic leukemia (B-CLL) tumor cells in the G0 cell cycle phase, BCR lower than normal B cells, and ZAP-70 in Syk deficient B-CLL, can replace the BCR signal to reconstruct Syk pathway to high expression of ZAP-70 . I room with four-color flow cytometry of ZAP-70 protein in CLL, with CD38 expression, discussed in the ZAP-70 expression in CLL and other prognostic characteristics of the correlation.24 cases the patients were from August 2004 -2005 hospital in March I have been diagnosed with B-CLL patients, 15 males and 9 females, aged 37-82 years, of which 15 cases of Binet A, Binet BC 9 cases the latter is the 6 patients newly diagnosed Binet BC period. From diagnosis to conduct the study, the average median time of 54 months, which Binet A period of 51 months, Binet BC period of 21 months. All patients with peripheral blood cells, peripheral blood smear and bone marrow cell morphology, multi-parameter flow cytometry immunophenotyping and chromosome analysis. Diagnosis and staging are based on "blood disease diagnosis and efficacy standards"  OK. Laboratory examination: Peripheral blood 10 109 / L, lymphocyte percentage 50%, the absolute value of 5 109 / L, bone marrow hyperplasia or apparent active lymphoc 40%, to mature lymphocyte predominance; immunophenotype: CD10-, CD19, CD5, CD23, CD20, FMC7-, and the exclusion of other diseases.
Reagents and equipment
Monoclonal antibodies including CD5-FITC, ZAP-70-PE, CD19-ECD, CD38-PC5 and its corresponding tags such as luciferase the same type of control, in addition to ZAP-70 and PE labeled isotype control products for the U.S. Caltag (clone 1E7 .2), the rest are French Immunotech monoclonal antibody products. Flow cytometry to Beckman-Coulter Epics XL-based company (USA), using Expo32-ADC analysis software.
Extracted fresh bone marrow or peripheral blood anticoagulant heparin (6 hours) to adjust the cell number to (0.5-1) 106/ml, take 100 l added CD5-FITC/CD19-ECD/CD38-CY5 the 20 l, dark for 15 minutes, plus Fix
Medical HEALTH "> Clinical Oncology Abstract B-cell chronic lymphocytic leukemia / small lymphocytic lymphoma treatment status reRecommended online full collection of this Yong Wai this [1,2]  Beijing Cancer Hospital, Internal Medicine  Institute of Clinical Oncology, Peking University, "the world of clinical medicine" 2008 Vol 29 No. 8 Survey Summary fast food prizes: B cell chronic lymphocytic leukemia (B-CLL) / small lymphocytic lymphoma (SLL) is the place in the lymphatic hematopoietic tissue, and cloning of the continuing proliferation of small lymphocytes and mature tumors (SLL). B-CLL/SLL current therapeutic indications for first-line chemotherapy in previously untreated patients choose to include a single nucleoside analogues fludarabine, alkylating agent (chlorambucil or cyclophosphamide) with or without a single past due Ghali resistance, and fludarabine-based or alkylating agent based combination chemotherapy with or without Gary rituximab. Number of pages: 6 page range :463-467 pages, 479 pages Keywords: B cell chronic lymphocytic leukemia, small lymphocytic lymphoma, fludarabine, chlorambucil chemotherapy rituximab subject classification: R733 .7 [medicine, HEALTH "Onco hematopoietic and lymphoid neoplasms dev leukemia] Related articles: subject
Friends Links: Automation Control Blog